Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

ClinicalTrials.gov ID: NCT03850574

Public ClinicalTrials.gov record NCT03850574. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 6, 2026, 2:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Study identification

NCT ID: NCT03850574
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Aptose Biosciences Inc.; Industry
Enrollment: 240 participants

Conditions and interventions

Conditions

Interventions

Azacitidine for Intravenous Infusion Drug
Tuspetinib Drug
Venetoclax Oral Tablet Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 10, 2019
Primary completion: Oct 31, 2026
Completion: Mar 31, 2027
Last update posted: Aug 25, 2025

2019 – 2027

United States locations

U.S. sites: 15
U.S. states: 9
U.S. cities: 15

Facility	City	State	ZIP	Site status
The Kirklin Clinic of UAB Hospital	Birmingham	Alabama	35233	Recruiting
City of Hope Comprehensive Cancer Center	Duarte	California	91010	Active, not recruiting
University of California Irvine	Irvine	California	92697	Recruiting
UCSD Moores Cancer Center	La Jolla	California	92093	Active, not recruiting
USC/Norris Comprehensive Cancer Center	Los Angeles	California	90033	Recruiting
Stanford Cancer Center	Palo Alto	California	94304	Recruiting
University of California, Davis	Sacramento	California	95817	Recruiting
Yale University	New Haven	Connecticut	06520	Recruiting
University of Miami - Miller School of Medicine	Miami	Florida	33136	Recruiting
Emory University	Atlanta	Georgia	30322	Active, not recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Active, not recruiting
Duke University Medical Center	Durham	North Carolina	27705	Recruiting
Cleveland Clinic - Taussig Cancer Center	Cleveland	Ohio	44106	Active, not recruiting
The Ohio State University Wexner Medical Center	Columbus	Ohio	43210	Recruiting
MD Anderson Cancer Center	Huston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03850574, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 25, 2025 · Synced May 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03850574 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →